These results are in agreement with those from previous studies in which trastuzumab was reported to inhibit HER2+ tumor growth by stimulating endocytosis and degradation of the receptor, with subsequent impairment of downstream signaling through PI3K/AKT and MAPK cascades [43]. The gene discussed is ERBB2; the disease is neoplasm.